Delfi Diagnostics, Inc.

DELFI Diagnostics develops blood-based cancer screening tests using artificial intelligence and whole-genome sequencing to analyze cell-free DNA fragmentation patterns. The company's FirstLook Lung test is designed to help identify individuals who should undergo low-dose CT screening for lung cancer in health systems, with reported 99.8% negative predictive value.